Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On June 21, 2019, Bill C-97 received Royal Assent. Bill C-97 includes amendments to the Food and Drugs Act, including a new framework for "Advanced Therapeutic Products"
On June 21, 2019, Bill C-97 received Royal Assent. Bill C-97 includes amendments to
the Food and Drugs Act, including a new framework for
“Advanced Therapeutic Products”, and will come into
force on a day to be fixed. On July 18, 2019, Health Canada opened
a consultation seeking feedback on what Health
Canada should consider in developing new clinical trial
regulations, as well as implementing the pathway for Advanced
Therapeutic Products. The consultation will close on August
30, 2019.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
